Vanessa F. Bonazzi

37 Kent Street
Woolloongabba, QLD 4102, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature.

Journal: Cell reports. Medicine

Published: December 28, 2024

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.

Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.

Journal: Genome medicine

Published: December 12, 2023

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.

The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.

Journal: Frontiers in immunology

Published: May 10, 2023

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.

Journal: The Journal of molecular diagnostics : JMD

Published: April 03, 2023

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition.

Journal: NPJ precision oncology

Published: January 25, 2023

C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.

C-reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients.

Journal: Asia-Pacific journal of clinical oncology

Published: December 01, 2021

ctDNA as a biomarker of progression in oesophageal adenocarcinoma.

ctDNA as a biomarker of progression in oesophageal adenocarcinoma.

Journal: ESMO open

Published: December 01, 2021

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.

Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels.

Journal: ESMO open

Published: October 21, 2021

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.

Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy.

Journal: Nature communications

Published: August 25, 2021

Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip.

Characterizing the Heterogeneity of Small Extracellular Vesicle Populations in Multiple Cancer Types via an Ultrasensitive Chip.

Journal: ACS sensors

Published: July 15, 2021

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.

Journal: Molecular cancer research : MCR

Published: December 20, 2020

Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.

Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer.

Journal: Genome medicine

Published: November 19, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026